{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:18:35Z","timestamp":1792660715621,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T00:00:00Z","timestamp":1563753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41591-019-0521-4","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T12:02:54Z","timestamp":1563796974000},"page":"1290-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":193,"title":["GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9760-2643","authenticated-orcid":false,"given":"Edoardo","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix J.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ingelfinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Arvaniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-6936","authenticated-orcid":false,"given":"Martin","family":"Diebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9269-2806","authenticated-orcid":false,"given":"Dunja","family":"Mrdjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez Al","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Claassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Derfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1541-7867","authenticated-orcid":false,"given":"Burkhard","family":"Becher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,22]]},"reference":[{"key":"521_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou, C. A., Fugger, L. & Friese, M. A. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15, 545\u2013558 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"521_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","volume":"8","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz, M., Derfuss, T., Hohlfeld, R. & Meinl, E. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 8, 613\u2013623 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"521_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fimmu.2013.00063","volume":"4","author":"C Chanvillard","year":"2013","unstructured":"Chanvillard, C., Jacolik, R. F., Infante-Duarte, C. & Nayak, R. C. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol. 4, 63 (2013).","journal-title":"Front Immunol."},{"key":"521_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneurol.2016.110","volume":"12","author":"MK Mishra","year":"2016","unstructured":"Mishra, M. K. & Yong, V. W. Myeloid cells\u2014targets of medication in multiple sclerosis. Nat. Rev. Neurol. 12, 539\u2013551 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"521_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/imr.12169","volume":"259","author":"M Kleinewietfeld","year":"2014","unstructured":"Kleinewietfeld, M. & Hafler, D. A. Regulatory T cells in autoimmune neuroinflammation. Immunol. Rev. 259, 231\u2013244 (2014).","journal-title":"Immunol. Rev."},{"key":"521_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(87)92863-7","volume":"1","author":"HS Panitch","year":"1987","unstructured":"Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1, 893\u2013895 (1987).","journal-title":"Lancet"},{"key":"521_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI114800","volume":"86","author":"T Olsson","year":"1990","unstructured":"Olsson, T. et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 86, 981\u2013985 (1990).","journal-title":"J. Clin. Invest."},{"key":"521_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","volume":"172","author":"JS Tzartos","year":"2008","unstructured":"Tzartos, J. S. et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172, 146\u2013155 (2008).","journal-title":"Am. J. Pathol."},{"key":"521_CR9","doi-asserted-by":"publisher","first-page":"241ra80","DOI":"10.1126\/scitranslmed.3008706","volume":"6","author":"R Noster","year":"2014","unstructured":"Noster, R. et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci. Transl. Med. 6, 241ra80 (2014).","journal-title":"Sci. Transl. Med."},{"key":"521_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6056","volume":"5","author":"FJ Hartmann","year":"2014","unstructured":"Hartmann, F. J. et al. Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nat. Commun. 5, 5056 (2014).","journal-title":"Nat. Commun."},{"key":"521_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2010.07.002","volume":"361","author":"O Ornatsky","year":"2010","unstructured":"Ornatsky, O. et al. Highly multiparametric analysis by mass cytometry. J. Immunol. Methods 361, 1\u201320 (2010).","journal-title":"J. Immunol. Methods"},{"key":"521_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.it.2012.02.010","volume":"33","author":"SC Bendall","year":"2012","unstructured":"Bendall, S. C., Nolan, G. P., Roederer, M. & Chattopadhyay, P. K. A deep profiler\u2019s guide to cytometry. Trends Immunol. 33, 323\u2013332 (2012).","journal-title":"Trends Immunol."},{"key":"521_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/eji.201847758","volume":"49","author":"E Galli","year":"2019","unstructured":"Galli, E. et al. The end of omics? High dimensional single cell analysis in precision medicine. Eur. J. Immunol. 49, 212\u2013220 (2019).","journal-title":"Eur. J. Immunol."},{"key":"521_CR14","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nbt.1991","volume":"29","author":"P Qiu","year":"2011","unstructured":"Qiu, P. et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 29, 886\u2013891 (2011).","journal-title":"Nat. Biotechnol."},{"key":"521_CR15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","volume":"162","author":"JH Levine","year":"2015","unstructured":"Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184\u2013197 (2015).","journal-title":"Cell"},{"key":"521_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytom. A 87, 636\u2013645 (2015).","journal-title":"Cytom. A"},{"key":"521_CR17","doi-asserted-by":"publisher","first-page":"E2770","DOI":"10.1073\/pnas.1408792111","volume":"111","author":"RV Bruggner","year":"2014","unstructured":"Bruggner, R. V., Bodenmiller, B., Dill, D. L., Tibshirani, R. J. & Nolan, G. P. Automated identification of stratifying signatures in cellular subpopulations. Proc. Natl Acad. Sci. USA 111, E2770\u2013E2777 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"521_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14825","volume":"8","author":"E Arvaniti","year":"2017","unstructured":"Arvaniti, E. & Claassen, M. Sensitive detection of rare disease-associated cell subsets via representation learning. Nat. Commun. 8, 14825 (2017).","journal-title":"Nat. Commun."},{"key":"521_CR19","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1084\/jem.20160897","volume":"213","author":"FJ Hartmann","year":"2016","unstructured":"Hartmann, F. J. et al. High-dimensional single-cell analysis reveals the immune signature of narcolepsy. J. Exp. Med. 213, 2621\u20132633 (2016).","journal-title":"J. Exp. Med."},{"key":"521_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature20810","volume":"542","author":"DA Rao","year":"2017","unstructured":"Rao, D. A. et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 542, 110\u2013114 (2017).","journal-title":"Nature"},{"key":"521_CR21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cyto.a.23030","volume":"89","author":"LM Weber","year":"2016","unstructured":"Weber, L. M. & Robinson, M. D. Comparison of clustering methods for high-dimensional single-cell flow and mass cytometry data. Cytom. A 89, 1084\u20131096 (2016).","journal-title":"Cytom. A"},{"key":"521_CR22","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0531-5565(03)00189-X","volume":"38","author":"P Pietschmann","year":"2003","unstructured":"Pietschmann, P. et al. The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp. Gerontol. 38, 1119\u20131127 (2003).","journal-title":"Exp. Gerontol."},{"key":"521_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1359-6101(02)00018-7","volume":"13","author":"ET Andreakos","year":"2002","unstructured":"Andreakos, E. T., Foxwell, B. M., Brennan, F. M., Maini, R. N. & Feldmann, M. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 13, 299\u2013313 (2002).","journal-title":"Cytokine Growth Factor Rev."},{"key":"521_CR24","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.4049\/jimmunol.1403243","volume":"194","author":"J Rasouli","year":"2015","unstructured":"Rasouli, J. et al. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-\u03b2 therapy. J. Immunol. 194, 5085\u20135093 (2015).","journal-title":"J. Immunol."},{"key":"521_CR25","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/cr.2014.155","volume":"24","author":"D Herndler-Brandstetter","year":"2014","unstructured":"Herndler-Brandstetter, D. & Flavell, R. A. Producing GM-CSF: a unique T helper subset? Cell Res. 24, 1379\u20131380 (2014).","journal-title":"Cell Res."},{"key":"521_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.4049\/jimmunol.1501928","volume":"196","author":"Y Cheng","year":"2016","unstructured":"Cheng, Y., Wong, M. T., van der Maaten, L. & Newell, E. W. Categorical analysis of human T cell heterogeneity with one-dimensional soli-expression by nonlinear stochastic embedding. J. Immunol. 196, 924\u2013932 (2016).","journal-title":"J. Immunol."},{"key":"521_CR27","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jaci.2015.04.008","volume":"136","author":"WE O\u2019Gorman","year":"2015","unstructured":"O\u2019Gorman, W. E. et al. Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J. Allergy Clin. Immunol. 136, 1326\u20131336 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"521_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"521_CR29","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"521_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","volume":"64","author":"GP Rice","year":"2005","unstructured":"Rice, G. P., Hartung, H. P. & Calabresi, P. A. Anti-\u03b14 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336\u20131342 (2005).","journal-title":"Neurology"},{"key":"521_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold, R. et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367, 1098\u20131107 (2012).","journal-title":"N. Engl. J. Med."},{"key":"521_CR32","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox, R. J. et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087\u20131097 (2012).","journal-title":"N. Engl. J. Med."},{"key":"521_CR33","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1212\/NXI.0000000000000076","volume":"2","author":"CM Spencer","year":"2015","unstructured":"Spencer, C. M., Crabtree-Hartman, E. C., Lehmann-Horn, K., Cree, B. A. & Zamvil, S. S. Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol. Neuroimmunol. Neuroinflamm. 2, e76 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"521_CR34","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1212\/NXI.0000000000000183","volume":"3","author":"CC Gross","year":"2016","unstructured":"Gross, C. C. et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e183 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"521_CR35","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.4049\/jimmunol.1601532","volume":"198","author":"Q Wu","year":"2017","unstructured":"Wu, Q. et al. Dimethyl fumarate selectively reduces memory T cells and shifts the balance between TH1\/TH17 and TH2 in multiple sclerosis patients. J. Immunol. 198, 3069\u20133080 (2017).","journal-title":"J. Immunol."},{"key":"521_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.4049\/jimmunol.1601649","volume":"198","author":"R Li","year":"2017","unstructured":"Li, R. et al. Dimethyl fumarate treatment mediates an anti-inflammatory shift in B cell subsets of patients with multiple sclerosis. J. Immunol. 198, 691\u2013698 (2017).","journal-title":"J. Immunol."},{"key":"521_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2017.09.009","volume":"86","author":"M Diebold","year":"2018","unstructured":"Diebold, M. et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. J. Autoimmun. 86, 39\u201350 (2018).","journal-title":"J. Autoimmun."},{"key":"521_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2353\/ajpath.2008.070918","volume":"172","author":"EE McCandless","year":"2008","unstructured":"McCandless, E. E. et al. Pathological expression of CXCL12 at the blood\u2013brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 172, 799\u2013808 (2008).","journal-title":"Am. J. Pathol."},{"key":"521_CR39","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbadis.2010.07.019","volume":"1812","author":"DW Holman","year":"2011","unstructured":"Holman, D. W., Klein, R. S. & Ransohoff, R. M. The blood\u2013brain barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta 1812, 220\u2013230 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"521_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","volume":"76","author":"MC Kowarik","year":"2011","unstructured":"Kowarik, M. C. et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76, 1214\u20131221 (2011).","journal-title":"Neurology"},{"key":"521_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s00415-013-7145-2","volume":"261","author":"MC Kowarik","year":"2014","unstructured":"Kowarik, M. C. et al. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. J. Neurol. 261, 130\u2013143 (2014).","journal-title":"J. Neurol."},{"key":"521_CR42","doi-asserted-by":"publisher","first-page":"1259425","DOI":"10.1126\/science.1259425","volume":"349","author":"MH Spitzer","year":"2015","unstructured":"Spitzer, M. H. et al. Immunology. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015).","journal-title":"Science"},{"key":"521_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.immuni.2015.08.010","volume":"43","author":"AL Croxford","year":"2015","unstructured":"Croxford, A. L. et al. The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. Immunity 43, 502\u2013514 (2015).","journal-title":"Immunity"},{"key":"521_CR44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.it.2015.08.004","volume":"36","author":"AL Croxford","year":"2015","unstructured":"Croxford, A. L., Spath, S. & Becher, B. GM-CSF in neuroinflammation: licensing myeloid cells for tissue damage. Trends Immunol. 36, 651\u2013662 (2015).","journal-title":"Trends Immunol."},{"key":"521_CR45","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.immuni.2019.04.006","volume":"50","author":"J Komuczki","year":"2019","unstructured":"Komuczki, J. et al. Fate-mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1\u03b2. Immunity 50, 1289\u20131304.e6 (2019).","journal-title":"Immunity"},{"key":"521_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.immuni.2017.01.007","volume":"46","author":"S Spath","year":"2017","unstructured":"Spath, S. et al. Dysregulation of the cytokine GM-CSF induces spontaneous phagocyte invasion and immunopathology in the central nervous system. Immunity 46, 245\u2013260 (2017).","journal-title":"Immunity"},{"key":"521_CR47","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ni.2027","volume":"12","author":"L Codarri","year":"2011","unstructured":"Codarri, L. et al. ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560\u2013567 (2011).","journal-title":"Nat. Immunol."},{"key":"521_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2017.12.017","volume":"317","author":"J Imitola","year":"2018","unstructured":"Imitola, J. et al. Elevated expression of granulocyte\u2013macrophage colony-stimulating factor receptor in multiple sclerosis lesions. J. Neuroimmunol. 317, 45\u201354 (2018).","journal-title":"J. Neuroimmunol."},{"key":"521_CR49","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/cr.2014.154","volume":"24","author":"W Sheng","year":"2014","unstructured":"Sheng, W. et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res. 24, 1387\u20131402 (2014).","journal-title":"Cell Res."},{"key":"521_CR50","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1212\/NXI.0000000000000117","volume":"2","author":"CS Constantinescu","year":"2015","unstructured":"Constantinescu, C. S. et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2, e117 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"521_CR51","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr, T. A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209, 1001\u20131010 (2012).","journal-title":"J. Exp. Med."},{"key":"521_CR52","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","volume":"178","author":"M Duddy","year":"2007","unstructured":"Duddy, M. et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178, 6092\u20136099 (2007).","journal-title":"J. Immunol."},{"key":"521_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic, I. et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell 175, 85\u2013100.e23 (2018).","journal-title":"Cell"},{"key":"521_CR54","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/brain\/awh680","volume":"129","author":"M Krumbholz","year":"2006","unstructured":"Krumbholz, M. et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129, 200\u2013211 (2006).","journal-title":"Brain"},{"key":"521_CR55","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1189\/jlb.1202598","volume":"73","author":"D Giunti","year":"2003","unstructured":"Giunti, D. et al. Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J. Leukoc. Biol. 73, 584\u2013590 (2003).","journal-title":"J. Leukoc. Biol."},{"key":"521_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jneuroim.2006.05.003","volume":"177","author":"TM Calderon","year":"2006","unstructured":"Calderon, T. M. et al. A role for CXCL12 (SDF-1\u03b1) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J. Neuroimmunol. 177, 27\u201339 (2006).","journal-title":"J. Neuroimmunol."},{"key":"521_CR57","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bbi.2017.03.008","volume":"64","author":"SM Restorick","year":"2017","unstructured":"Restorick, S. M. et al. CCR6+ TH cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic TH1 cells and GM-CSF-only-secreting TH cells. Brain Behav. Immun. 64, 71\u201379 (2017).","journal-title":"Brain Behav. Immun."},{"key":"521_CR58","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1093\/brain\/awp289","volume":"132","author":"V Brucklacher-Waldert","year":"2009","unstructured":"Brucklacher-Waldert, V., Stuerner, K., Kolster, M., Wolthausen, J. & Tolosa, E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132, 3329\u20133341 (2009).","journal-title":"Brain"},{"key":"521_CR59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg, M. D. et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 360, 449\u2013453 (2018).","journal-title":"Science"},{"key":"521_CR60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69, 292\u2013302 (2011).","journal-title":"Ann. Neurol."},{"key":"521_CR61","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1177\/1352458513488232","volume":"19","author":"C Teunissen","year":"2013","unstructured":"Teunissen, C. et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult. Scler. 19, 1802\u20131809 (2013).","journal-title":"Mult. Scler."},{"key":"521_CR62","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"key":"521_CR63","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.4049\/jimmunol.1402661","volume":"194","author":"HE Mei","year":"2015","unstructured":"Mei, H. E., Leipold, M. D., Schulz, A. R., Chester, C. & Maecker, H. T. Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry. J. Immunol. 194, 2022\u20132031 (2015).","journal-title":"J. Immunol."},{"key":"521_CR64","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316\u2013333 (2015).","journal-title":"Nat. Protoc."},{"key":"521_CR65","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cyto.a.22271","volume":"83","author":"R Finck","year":"2013","unstructured":"Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytom. A 83, 483\u2013494 (2013).","journal-title":"Cytom. A"},{"key":"521_CR66","unstructured":"R Development Core Team R: A language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2010)."},{"key":"521_CR67","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487\u2013502.e15 (2017).","journal-title":"Cell"},{"key":"521_CR68","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/75022","volume":"6","author":"MC Poznansky","year":"2000","unstructured":"Poznansky, M. C. et al. Active movement of T cells away from a chemokine. Nat. Med. 6, 543\u2013548 (2000).","journal-title":"Nat. Med."},{"key":"521_CR69","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/nbt1209-1135","volume":"27","author":"WS Noble","year":"2009","unstructured":"Noble, W. S. How does multiple testing correction work? Nat. Biotechnol. 27, 1135\u20131137 (2009).","journal-title":"Nat. Biotechnol."},{"key":"521_CR70","unstructured":"McDonald, J. Handbook of Biological Statistics 3rd edn (Sparky House Publishing, 2014)."},{"key":"521_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0521-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:59:49Z","timestamp":1684605589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,22]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0521-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736231988.793563546","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,22]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.O. has received unrestricted MS research grants, in addition to lecture and or advisory board honoraria, from Biogen, Novartis, Sanofi, Merck and Roche. M.D. received speaker honoraria from Biogen Switzerland, which were used exclusively for research purposes. F.P. has received research grants from Biogen, Genzyme, Merck and Novartis, and fees for serving as Data Monitoring Committee Chair in clinical trials with Parexel. T.D. received financial compensation for participation in advisory boards, steering committees and data safety monitoring boards, and for consultation for Novartis Pharmaceuticals, Merck, Biogen, Celgene, GeNeuro, Mitsubishi Tanabe Pharma, MedDay, Roche and Sanofi Genzyme. T.D. also received research support from Novartis, Biogen, the National Swiss Science Foundation, the European Union and the Swiss MS Society.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}